Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KeyVibe-002: MK-7684A (Vibostolimab/Pembrolizumab) +/- Docetaxel in Metastatic NSCLC
NCT04725188Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2021
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
A Phase 2 trial of vibostolimab, pembrolizumab, sponsored by Merck & Co.. Started Apr 2021; status: completed.
02
Drugs
vibostolimabpembrolizumab
Beyond the preview
Go deeper on NCT04725188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04725188.